R
Robert Milroy
Researcher at Glasgow Royal Infirmary
Publications - 65
Citations - 3073
Robert Milroy is an academic researcher from Glasgow Royal Infirmary. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 27, co-authored 64 publications receiving 2884 citations. Previous affiliations of Robert Milroy include Stobhill Hospital & National Health Service.
Papers
More filters
Journal ArticleDOI
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.
Heather Anderson,Penelope Hopwood,Richard Stephens,Nick Thatcher,B Cottier,M Nicholson,Robert Milroy,Tim Maughan,S. Falk,M G Bond,Paul A Burt,C K Connolly,M B McIllmurray,J Carmichael +13 more
TL;DR: Patients treated with gemcitabine + BSC reported better QL and reduced disease-related symptoms compared with those receiving BSC alone, and improvements in patient-assessed QL were significant in magnitude and were sustained.
Journal ArticleDOI
The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer.
Hazel R. Scott,Donald C. McMillan,L M Forrest,Duncan J.F Brown,Colin S. McArdle,Robert Milroy +5 more
TL;DR: The results indicate that the majority of patients with inoperable non-small cell lung cancer have evidence of a systemic inflammatory response and an increase in the magnitude of the systemicinflammatory response resulted in greater weight loss, poorer performance status, more fatigue and poorer survival.
Journal ArticleDOI
Quality of life in lung cancer patients - As an important prognostic factor
TL;DR: This study confirmed that pre-diagnosis quality of life was a significant predictor of survival and should be considered as a clinical status which has to be established by physicians before treatment starts.
Journal ArticleDOI
Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life.
Stephen G. Spiro,Robin M. Rudd,Robert L. Souhami,Julia Brown,D.J. Fairlamb,N.H. Gower,L Maslove,Robert Milroy,Vicky Napp,Mahesh K. B. Parmar,M.D. Peake,Richard Stephens,H. Thorpe,David A. Waller,P West +14 more
TL;DR: The survival benefit seen in this trial was entirely consistent with the NSCLC meta-analysis and subsequent similarly designed large trials, and the regimens used proved to be cost effective, the extra cost of chemotherapy being offset by longer survival.
Journal ArticleDOI
The relationship between weight loss and interleukin 6 in non-small-cell lung cancer
TL;DR: Markers of the inflammatory response, interleukin 6, C-reactive protein, albumin and full blood count, were measured in non-small-cell lung cancer patients with and without weight loss, consistent with interleucin 6 and the acute phase response promoting weight loss in NSCLC.